Denali Therapeutics Inc. (NASDAQ:DNLI) Position Boosted by Cinctive Capital Management LP

Cinctive Capital Management LP lifted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,094 shares of the company's stock after acquiring an additional 36,771 shares during the quarter. Cinctive Capital Management LP owned 0.10% of Denali Therapeutics worth $4,343,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its position in Denali Therapeutics by 879.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock worth $48,000 after buying an additional 1,847 shares during the last quarter. CWM LLC boosted its stake in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after buying an additional 654 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Denali Therapeutics during the 3rd quarter valued at $73,000. Assetmark Inc. grew its holdings in shares of Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after purchasing an additional 580 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock worth $152,000 after buying an additional 920 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on DNLI. Jefferies Financial Group upped their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, November 1st. JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Denali Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald cut shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. Finally, Raymond James restated a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $38.90.

Denali Therapeutics Trading Down 3.9 %

Shares of NASDAQ:DNLI traded down $1.01 during midday trading on Tuesday, hitting $24.62. 212,898 shares of the company's stock were exchanged, compared to its average volume of 1,063,287. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. The stock has a 50 day moving average price of $27.20 and a 200-day moving average price of $24.57.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the company earned ($0.72) earnings per share. As a group, equities research analysts expect that Denali Therapeutics Inc. will post -2.69 EPS for the current fiscal year.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 15,558 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the sale, the insider now directly owns 178,066 shares of the company's stock, valued at $5,325,954.06. This trade represents a 8.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the company's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now directly owns 235,807 shares in the company, valued at $6,529,495.83. This trade represents a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,578 shares of company stock valued at $2,474,440 over the last ninety days. Company insiders own 7.90% of the company's stock.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.